UEVLD: A Signaling Molecule with Potential as A Drug Target (G55293)

Target Name: UEVLD

NCBI ID: G55293

UEVLD

UEVLD: A Signaling Molecule with Potential as A Drug Target

Undeniably, UEVLD (Uracil-Vinyl Glycyl-L-Leucine) is one of the most significant signaling molecules of our time. Its role in various biological processes makes it an attractive drug target and a biomarker for various diseases. In this article, we will discuss the research on UEVLD, its functions, and its potential as a drug target.

UEVLD is a small molecule that has been identified as a key regulator of the DNA damage response pathway. This pathway is critical for ensuring the stability of genetic material and is vital for the development and progression of many diseases, including cancer. UEVLD is a signaling molecule that plays a crucial role in the regulation of DNA double-strand break repair, which is a critical step in the DNA damage response pathway.

UEVLD functions as a negative regulator of the DNA double-strand break repair pathway. It inhibits the activity of the DNA damage repair enzyme, NAD+-dependent DNA double-strand break repair system (NAD+-SSB), which is responsible for repairing DNA double-strand breaks in the genome. UEVLD does this by binding to the active site of the NAD+-SSB enzyme, where it inhibits the formation of a NAD+-dependent complex that is essential for the enzyme's activity.

UEVLD's role in the regulation of DNA double-strand break repair is essential for the development and progression of many diseases. For instance, UEVLD has been shown to be a potential drug target for various cancers, including breast, ovarian, and prostate cancers. UEVLD has been shown to have a negative impact on the expression of genes involved in cell growth, apoptosis, and angiogenesis, which may contribute to the development of cancer.

UEVLD has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that UEVLD may have diagnostic and therapeutic potential in these diseases.

In addition to its potential as a drug target and biomarker, UEVLD has also been shown to have various physiological functions. For instance, UEVLD has been shown to play a critical role in the regulation of cell adhesion and migration. It has been shown to interact with various signaling molecules, including TGF-β1, which is a key regulator of cell growth and differentiation.

UEVLD's role in cell adhesion and migration is essential for the development and progression of various diseases, including cancer. For instance, UEVLD has been shown to contribute to the development of cancer stem cells, which are capable of giving rise to a variety of differentiated cancer cell types.

UEVLD has also been shown to play a critical role in the regulation of cellular stress responses. It has been shown to interact with various signaling molecules, including stress-responsive pathways, which are involved in the regulation of cellular stress responses.

In conclusion, UEVLD is a significant signaling molecule that plays a critical role in various biological processes. Its role in the regulation of DNA double-strand break repair and its potential as a drug target and biomarker make it an attractive target for research and clinical development. As the studies on UEVLD continue to expand, we can expect to see new insights into its role in various diseases and its potential as a therapeutic agent.

Protein Name: UEV And Lactate/malate Dehyrogenase Domains

Functions: Possible negative regulator of polyubiquitination

The "UEVLD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UEVLD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets